Bridging Therapy for Dabigatran

Introduction to Dabigatran Management

The American College of Chest Physicians recommends that bridging therapy is generally not required for patients on dabigatran who need temporary interruption for procedures, due to dabigatran's short half-life and predictable pharmacokinetics 1

The timing of dabigatran interruption before procedures depends on renal function, with dabigatran being primarily eliminated by the kidneys, and the bleeding risk of the procedure, with higher bleeding risk requiring longer interruption 2, 3
For patients with normal or mildly impaired renal function, low bleeding risk procedures require dabigatran interruption 2 days before surgery, while high bleeding risk procedures require interruption 3 days before surgery 2, 3
For patients with moderate renal impairment, low bleeding risk procedures require dabigatran interruption 3 days before surgery, while high bleeding risk procedures require interruption 4-5 days before surgery 2, 3

The rapid offset and rapid onset of action of dabigatran obviate the need for heparin bridging with short-acting anticoagulants such as UFH or LMWH in the perioperative setting, with evidence showing increased bleeding risk without reduction in thromboembolic events 1

The timing of dabigatran resumption depends on the bleeding risk of the procedure, with low bleeding risk procedures allowing resumption on the day after surgery at full dose, and high bleeding risk procedures requiring resumption 2-3 days after surgery at full dose 1, 4
For patients at high risk for thromboembolism undergoing high bleeding risk procedures, consider administering a reduced dose of dabigatran on the evening after surgery and on the first postoperative day 4

For minor procedures, it may be reasonable to continue dabigatran, though clinical data supporting this approach are limited 4
The rapid peak anticoagulant effect of dabigatran requires cautious postoperative resumption, similar to resuming treatment-dose LMWH 4

Avoid unnecessary bridging, as dabigatran does not require bridging therapy due to its predictable pharmacokinetics and short half-life 1
Avoid premature resumption after high bleeding risk procedures, as this increases bleeding risk 1, 4
Avoid delayed resumption after low bleeding risk procedures in high thrombotic risk patients, and avoid full-dose resumption immediately after high bleeding risk procedures, considering reduced initial dosing instead 4